MX2011008850A - Derivados de piperidina como antagonistas del receptor de neuroquinina 3 (nk3). - Google Patents
Derivados de piperidina como antagonistas del receptor de neuroquinina 3 (nk3).Info
- Publication number
- MX2011008850A MX2011008850A MX2011008850A MX2011008850A MX2011008850A MX 2011008850 A MX2011008850 A MX 2011008850A MX 2011008850 A MX2011008850 A MX 2011008850A MX 2011008850 A MX2011008850 A MX 2011008850A MX 2011008850 A MX2011008850 A MX 2011008850A
- Authority
- MX
- Mexico
- Prior art keywords
- receptor antagonists
- piperidine derivatives
- compounds
- adhd
- psychosis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
- C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
La presente solicitud se refiere a los compuestos de la fórmula (I) en donde las definiciones son como se describe en la reivindicación 1. Se ha descubierto que los presentes compuestos son antagonistas del receptor de NK-3 con gran potencial para el tratamiento de la depresión, dolor, psicosis, enfermedad de Parkinson, esquizofrenia, ansiedad y trastorno de déficit de atención/hiperactividad (ADHD).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09155585 | 2009-03-19 | ||
| PCT/EP2010/053417 WO2010106081A1 (en) | 2009-03-19 | 2010-03-16 | Piperidine derivatives as nk3 receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2011008850A true MX2011008850A (es) | 2011-09-28 |
Family
ID=42161621
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2011008850A MX2011008850A (es) | 2009-03-19 | 2010-03-16 | Derivados de piperidina como antagonistas del receptor de neuroquinina 3 (nk3). |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US8324250B2 (es) |
| EP (1) | EP2408745B1 (es) |
| JP (1) | JP5452627B2 (es) |
| KR (1) | KR101383538B1 (es) |
| CN (1) | CN102356065B (es) |
| AU (1) | AU2010224865B2 (es) |
| BR (1) | BRPI1013617A2 (es) |
| CA (1) | CA2749650A1 (es) |
| ES (1) | ES2505190T3 (es) |
| IL (1) | IL213982A0 (es) |
| MX (1) | MX2011008850A (es) |
| SG (1) | SG174876A1 (es) |
| WO (1) | WO2010106081A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8399676B2 (en) * | 2009-07-30 | 2013-03-19 | Hoffman-La Roche Inc. | Piperidine derivatives |
| US8258158B2 (en) | 2009-09-11 | 2012-09-04 | Hoffmann-La Roche Inc. | HSL inhibitors useful in the treatment of diabetes |
| CN102827056B (zh) * | 2012-09-03 | 2014-07-23 | 华东理工大学 | N-芳基取代吡咯烷酮衍生物及其用途 |
| US20150272927A1 (en) * | 2012-12-03 | 2015-10-01 | University Of Washington Through Its Center For Commercialization | Methods and compositions for treating vasomotor symptoms |
| KR20160100329A (ko) | 2013-12-20 | 2016-08-23 | 3-브이 바이오사이언시스, 인코포레이티드 | 지질 합성의 헤테로사이클릭 조절물질 및 이들의 조합물 |
| EP3183248B1 (en) | 2014-08-21 | 2020-11-11 | Bristol-Myers Squibb Company | Tied-back benzamide derivatives as potent rock inhibitors |
| GB201601301D0 (en) * | 2016-01-25 | 2016-03-09 | Takeda Pharmaceutical | Novel compounds |
| US11178872B2 (en) | 2016-05-09 | 2021-11-23 | Nippon Soda Co., Ltd. | Cyclic amine compound and pest control agent |
| CA3257803A1 (en) | 2022-06-13 | 2025-04-04 | Alivexis, Inc. | AZACYCLOLAKYL CARBONYL CYCLIC AMINE COMPOUND |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA004704B1 (ru) | 1999-05-24 | 2004-06-24 | Мицубиси Фарма Корпорейшн | Производные феноксипропиламина |
| JP4323169B2 (ja) * | 2001-02-28 | 2009-09-02 | メルク エンド カムパニー インコーポレーテッド | メラノコルチン−4受容体作働薬としてのアシル化ピペリジン誘導体 |
| KR100960827B1 (ko) | 2001-12-20 | 2010-06-08 | 오에스아이 파마슈티컬스, 인코포레이티드 | 피롤로피리미딘 A₂b 선택성 길항 화합물, 그의 합성방법 및 용도 |
| TW200403058A (en) * | 2002-04-19 | 2004-03-01 | Bristol Myers Squibb Co | Heterocyclo inhibitors of potassium channel function |
| JP4041153B2 (ja) | 2003-05-07 | 2008-01-30 | ファイザー・プロダクツ・インク | カンナビノイド受容体リガンドとその使用 |
| WO2004110996A1 (en) * | 2003-06-19 | 2004-12-23 | Pfizer Products Inc. | Nk1 antagonist |
| JP4713474B2 (ja) * | 2003-08-15 | 2011-06-29 | ハー・ルンドベック・アクチエゼルスカベット | Nk3受容体アンタゴニストとしてのシクロプロピル誘導体 |
| WO2008068159A1 (en) * | 2006-12-07 | 2008-06-12 | F. Hoffmann-La Roche Ag | Spiro-piperidine derivatives |
| US7470684B2 (en) * | 2007-01-03 | 2008-12-30 | Hoffmann-La Roche Inc. | Spiropiperidine derivatives as NK3 antagonists |
| US8063075B2 (en) * | 2008-06-10 | 2011-11-22 | Hoffmann-La Roche Inc. | Pyrrolidine ether derivatives as NK3 receptor antagonists |
-
2010
- 2010-03-11 US US12/721,587 patent/US8324250B2/en not_active Expired - Fee Related
- 2010-03-16 EP EP10708576.3A patent/EP2408745B1/en not_active Not-in-force
- 2010-03-16 CN CN201080012389.1A patent/CN102356065B/zh not_active Expired - Fee Related
- 2010-03-16 ES ES10708576.3T patent/ES2505190T3/es active Active
- 2010-03-16 SG SG2011067378A patent/SG174876A1/en unknown
- 2010-03-16 WO PCT/EP2010/053417 patent/WO2010106081A1/en not_active Ceased
- 2010-03-16 CA CA2749650A patent/CA2749650A1/en not_active Abandoned
- 2010-03-16 KR KR1020117021436A patent/KR101383538B1/ko not_active Expired - Fee Related
- 2010-03-16 JP JP2011553477A patent/JP5452627B2/ja not_active Expired - Fee Related
- 2010-03-16 MX MX2011008850A patent/MX2011008850A/es active IP Right Grant
- 2010-03-16 BR BRPI1013617A patent/BRPI1013617A2/pt not_active Application Discontinuation
- 2010-03-16 AU AU2010224865A patent/AU2010224865B2/en not_active Ceased
-
2011
- 2011-07-07 IL IL213982A patent/IL213982A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP5452627B2 (ja) | 2014-03-26 |
| US20100256126A1 (en) | 2010-10-07 |
| KR101383538B1 (ko) | 2014-04-11 |
| US8324250B2 (en) | 2012-12-04 |
| AU2010224865B2 (en) | 2013-09-05 |
| SG174876A1 (en) | 2011-11-28 |
| EP2408745A1 (en) | 2012-01-25 |
| CN102356065B (zh) | 2014-10-01 |
| ES2505190T3 (es) | 2014-10-09 |
| IL213982A0 (en) | 2011-08-31 |
| CA2749650A1 (en) | 2010-09-23 |
| CN102356065A (zh) | 2012-02-15 |
| JP2012520270A (ja) | 2012-09-06 |
| BRPI1013617A2 (pt) | 2016-04-19 |
| WO2010106081A1 (en) | 2010-09-23 |
| EP2408745B1 (en) | 2014-07-16 |
| KR20110117235A (ko) | 2011-10-26 |
| AU2010224865A1 (en) | 2011-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2011008850A (es) | Derivados de piperidina como antagonistas del receptor de neuroquinina 3 (nk3). | |
| MX2020012825A (es) | Compuestos multiciclicos y metodos de uso de los mismos. | |
| NZ603789A (en) | Heteroaryl compounds and methods of use thereof | |
| MX2011009369A (es) | 2-mercaptoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3. | |
| MX342161B (es) | Compuestos antagonistas selectivos de receptor nk-3 novedosos, composicion farmaceutica y metodos para utilizarse en trastornos transmitidos por receptores nk-3. | |
| PH12012500881A1 (en) | Antibodies binding preferentially human csf1r extracellular domain 4 and their use | |
| UA102251C2 (ru) | Производные аминодигидротиазина как ингибиторы васе для лечения болезни альцгеймера | |
| PH12013500247A1 (en) | Heterocyclic compound and use thereof | |
| ATE544767T1 (de) | Triazoloä4,5-düpyramidinderivate und deren verwendung als purinrezeptorantagonisten | |
| EA201071234A1 (ru) | Производные изохинолинона в качестве nk3 антагонистов | |
| IL202236A0 (en) | Prolinamide derivatives as nk3 antagonists | |
| MX2011006006A (es) | Compuestos, composicion farmaceutica y metodos para utilizarse en el tratamiento de trastornos metabolicos. | |
| MX2011008602A (es) | Metodos de tratamiento de condiciones relacionadas con el cabello. | |
| MX368459B (es) | Nuevas composiciones para prevenir y/o tratar trastornos degenerativos del sistema nervioso central. | |
| MY161473A (en) | Compositions, synthesis, and methods of utilizing arylpiperazine derivatives | |
| TW200942535A (en) | Novel compounds as cannabinoid receptor ligands | |
| MX2010002899A (es) | Derivados de azaciclilisoquinolinona e isoindolinona como antagonistas de la histamina-3. | |
| MX2009003645A (es) | Azaciclilaminas n-sustituidas como antagonistas de histamina-3. | |
| MX2011008825A (es) | 3-aminoisoxazolopiridinas sustituidas como moduladores de kcnq2/3. | |
| MX2009012506A (es) | Composiciones, sintesis, y metodos para utilizar agentes antipsicoticos atipicos basados en quinolinona. | |
| MX2011010782A (es) | Compuestos agonistas del receptor 5-ht4 para el tratamiento de trastornos cognitivos. | |
| JO2682B1 (en) | Derivatives of alkynil-8.1-naphthayridone, preparations thereof and therapeutic use thereof | |
| TN2012000281A1 (en) | Mglu2 agonists | |
| MX2011008662A (es) | 2-mercapto-3-aminopiridinas sustituidas como moduladores de kcnq2/3. | |
| MX2011009338A (es) | 3-amino-2-mercaptoquinolinas sustituidas como moduladores de kcnq2/3. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |